Riad Ahmed Ibrahim net worth and biography

Riad Ibrahim Biography and Net Worth

Insider of Takeda Pharmaceutical

Ramy Riad, MBA, is the president of Takeda’s Plasma-Derived Therapies (PDT) Business Unit.

A global biopharmaceutical leader with more than 20 years of experience spanning strategy, finance, operations and market access, Ramy brings deep expertise in the plasma industry.

Most recently, he served as the senior vice president and CFO, Finance, Strategy, and Operations for the PDT Business Unit, where he helped shape Takeda’s end-to-end plasma value chain strategy. He also helped build an integrated operating model spanning plasma collection, manufacturing, R&D, strategy and commercial operations—strengthening alignment, accountability and performance through significant industry and supply chain disruption during the COVID-19 pandemic. Earlier at Takeda, Ramy led international commercial finance across eight regions, 106 countries, and 60 affiliates, driving commercial execution, market penetration, and organizational integration.

Prior to joining Takeda, he held multiple leadership roles at Abbott, Merck, and Sanofi Aventis, working across global market access, pricing, reimbursement, and institutional strategy.

Ramy holds an MBA in Finance from Southern New Hampshire University and a bachelor’s degree in Accounting and Business Administration from Cairo University.

What is Riad Ahmed Ibrahim's net worth?: The estimated net worth of Riad Ahmed Ibrahim is at least $1.79 million as of August 10th, 2026. Ibrahim owns 102,588 shares of Takeda Pharmaceutical stock worth more than $1,788,622 as of August 13th. This net worth estimate does not reflect any other investments that Ibrahim may own. Learn More about Riad Ahmed Ibrahim's net worth.
How do I contact Riad Ahmed Ibrahim?: The corporate mailing address for Ibrahim and other Takeda Pharmaceutical executives is 1-1 NIHONBASHI-HONCHO 2-CHOME CHUO-KU, TOKYO M0, 103-8668. Takeda Pharmaceutical can also be reached via phone at (166) 204-2111 and via email at [email protected]. Learn More on Riad Ahmed Ibrahim's contact information.
Has Riad Ahmed Ibrahim been buying or selling shares of Takeda Pharmaceutical?: In the last ninety days, Riad Ahmed Ibrahim has sold $124,436.70 of Takeda Pharmaceutical stock. Most recently, Ramy Riad Ahmed Ibrahim sold 7,277 shares of the business's stock in a transaction on Monday, August 10th. The shares were sold at an average price of $17.10, for a transaction totalling $124,436.70. Following the completion of the sale, the insider now directly owns 102,588 shares of the company's stock, valued at $1,754,254.80. Learn More on Riad Ahmed Ibrahim's trading history.
Who are Takeda Pharmaceutical's active insiders?: Takeda Pharmaceutical's insider roster includes Lauren Duprey (Chief Transformation Officer), Samaan Farajallah (Insider), Anne Furney (General Counsel), Deidre Greenway (Insider), Riad Ibrahim (Insider), Julie Kim (Representative Director – President and CEO), Agosti Pignagnoli (Insider), Giles Platford (President, International Business Unit), Gabriele Ricci (Insider), and Elaine Shannon (President, Global Supply & Quality). Learn More on Takeda Pharmaceutical's active insiders.
Are insiders buying or selling shares of Takeda Pharmaceutical?: During the last twelve months, insiders at the sold shares 11 times. They sold a total of 444,100 shares worth more than $7,594,110.00. The most recent insider tranaction occured on August, 10th when insider Ramy Riad Ahmed Ibrahim sold 7,277 shares worth more than $124,436.70. Insiders at Takeda Pharmaceutical own 0.0% of the company. Learn More about insider trades at Takeda Pharmaceutical.
Information on this page was last updated on 8/10/2026.

Riad Ahmed Ibrahim Insider Trading History at Takeda Pharmaceutical

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/10/2026	Sell	7,277	$17.10	$124,436.70	102,588

Riad Ahmed Ibrahim Buying and Selling Activity at Takeda Pharmaceutical

Takeda Pharmaceutical Company Overview

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.

Today's Range

Now: $17.42

$17.38

$17.47

50 Day Range

MA: $16.49

$15.41

$17.78

2 Week Range

Now: $17.42

$12.99

$18.90

Volume

633,062 shs

Average Volume

3,168,977 shs

Market Capitalization

$55.80 billion

P/E Ratio

51.24

Dividend Yield

2.75%

Beta

N/A